Jennifer A. Woyach, MD, spoke about the phase 3 AO41202 study, which investigated different ibrutinib regimens for elderly patients with chronic lymphocytic leukemia.
During the 2021 American Society of Hematology Annual Meeting, Jennifer A. Woyach, MD, associate professor in the Division of Hematology at The Ohio State University, discussed previously reported results of the phase 3 AO41202 study (NCT01886872), which looked to treat patients over 65 years of age who had not received prior therapy with ibrutinib (Imbruvica) regimens or chemoimmunotherapy for chronic lymphocytic leukemia (CLL). Woyach discusses prior results in anticipation of updated data that will be presented at the meeting.
The AO41202 study is a National Clinical Trials Network [NCTN]-sponsored phase 3 trial led by the Alliance for Clinical Trials in Oncology. In this study, we looked at the optimal care of older patients with previously untreated CLL. This study is for patients who are age 65 or older who had not received prior CLL therapy. We randomized them 1:1:1 for treatment with bendamustine plus rituximab, or ibrutinib given alone or ibrutinib given in combination with rituximab. The primary results of the study showed that either regimen containing ibrutinib showed superior progression-free survival to bendamustine and rituximab, and there was no difference between the 2 ibrutinib containing regimens.
Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517-2528. doi:10.1056/NEJMoa1812836